Ensysce Biosciences Initiates Pivotal Phase 3 for PF614, Advances MPAR with FDA Breakthrough Therapy Support
ENSC sits 61% above its 52-week low of $0.314.
Summary
Ensysce Biosciences reported its fourth quarter and full year 2025 financial results, though the primary focus of the announcement was on significant operational and clinical milestones. The company initiated a pivotal Phase 3 clinical trial for its lead drug candidate, PF614, an abuse-deterrent oxycodone. Additionally, Ensysce advanced its PF614-MPAR program, which combines abuse deterrence with overdose protection, receiving positive feedback from the FDA, including support for overdose-protection labeling and leveraging its Breakthrough Therapy designation. These clinical and regulatory advancements are material for a clinical-stage pharmaceutical company, indicating progress towards potential commercialization and strengthening its pipeline, which also includes a new candidate for opioid use disorder. This positive operational update provides a counter-narrative to the recent director resignation.
At the time of this announcement, ENSC was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.31 to $4.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.